

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/R640324A2EBEN.html>

Date: August 2018

Pages: 73

Price: US\$ 3,500.00 (Single User License)

ID: R640324A2EBEN

Abstracts

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H2 2018

SUMMARY

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Retinoic acid receptor beta (RARB) is a nuclear receptor that is encoded by the RARB gene. RARB bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as anregulate activator of gene expression due to weak binding to co-repressors. It is required for skeletal growth, matrix homeostasis and growth plate functions.

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3, 6, 4 and 1 respectively.

Similarly, the universities portfolio in Phase I stages comprises 1 molecules,

respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Immunology, Respiratory, Central Nervous System, Hematological Disorders, Metabolic Disorders, Oncology and Ophthalmology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Breast Cancer, Germ Cell Tumors, Hyperlipidemia, Inflammatory Bowel Disease, Myelodysplastic Syndrome, Neuroblastoma, Neutropenia, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinopathy Of Prematurity, Sarcomas, Spinal Cord Injury, Traumatic Nerve Injury and Type 2 Diabetes.

The latest report Retinoic Acid Receptor Beta - Pipeline Review, H2 2018, outlays comprehensive information on the Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)

The report reviews Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics under development by companies and

universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics and enlists all their major and minor projects

The report assesses Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Overview

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Companies

Involved in Therapeutics Development

3SBio Inc

Bausch Health Companies Inc

Lee's Pharmaceutical Holdings Ltd

Phosphagenics Ltd

Promius Pharma LLC

Sol-Gel Technologies Ltd

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Drug Profiles
(adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(adapalene + clindamycin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(clindamycin phosphate + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(halobetasol propionate + tazarotene) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(TPX-6001 + tretinoin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AC-261066 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alitretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCL-286 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBD-073 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamibarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Dormant Products

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Discontinued Products

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Product Development Milestones

Featured News & Press Releases

Jul 10, 2018: Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018

Jun 18, 2018: FDA declines to approve Valeant's plaque psoriasis lotion

Jun 18, 2018: FDA Issues Complete Response Letter For DUOBRII (Halobetasol Propionate and Tazarotene) Lotion

Apr 09, 2018: Ortho Dermatologics Announces Publication of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII In The Journal of the American Academy of Dermatology

Feb 15, 2018: Sol-Gel's Phase 2 Data on TWIN to be Presented at the 2018 American Academy of Dermatology Annual Meeting

Jan 22, 2018: Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARa Agonist

Jan 12, 2018: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

Jan 02, 2018: Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARa Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients

Dec 10, 2017: Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients

Nov 09, 2017: Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris

Nov 02, 2017: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment

Nov 01, 2017: Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 At ASH Annual Meeting

Oct 05, 2017: Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML

Sep 29, 2017: Syros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AML

Sep 28, 2017: A novel RARb agonist for spinal cord injury receives funding for a phase 1 trial from the MRC-DPFS

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by 3SBio Inc, H2 2018
Pipeline by Bausch Health Companies Inc, H2 2018
Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
Pipeline by Phosphagenics Ltd, H2 2018
Pipeline by Promius Pharma LLC, H2 2018
Pipeline by Sol-Gel Technologies Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

3SBio Inc

Bausch Health Companies Inc

Lee's Pharmaceutical Holdings Ltd

Phosphagenics Ltd

Promius Pharma LLC

Sol-Gel Technologies Ltd

I would like to order

Product name: Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/R640324A2EBEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R640324A2EBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970